The alterations of gene expression of interleukin‐36α and interleukin‐37 between alopecia areata patients and healthy controls

Marie, Radwa El‐Sayed Mahmoud; Atwa, Mona; Gomaa, Amal H. A.; Abdelhamid, Alaa Eldin S; Eyada, Moustafa Mk

doi:10.1111/ajd.13638

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the Letter To The Editors e431 relatively short follow-up, the low sample size and the long-lasting response to the adalimumab originator at the time of the shift for many patients, the results are in line with previous comparability studies 1,3,4,5 and demonstrate that the biosimilar adalimumab has shown not to be less effective than the originator and the transition to biosimilar adalimumab in psoriasis patients treated with the originator is a safe and effective choice in a real-life setting of moderate to severe psoriasis patients as previously observed in other biologic treatments, in particular infliximab. 6 The only difference we observed was a significant worsening of the assessment of pain in a subpopulation of patients with BMI> 25 between T0 and T1 suggesting the need of further evaluations and objective data, also with a multi-specialist team.…”

mentioning

confidence: 62%

Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real‐life experience in a tertiary referral centre

et al. 2021

View full text Add to dashboard Cite

mentioning

confidence: 62%

Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real‐life experience in a tertiary referral centre

et al. 2021

View full text Add to dashboard Cite

“…Furthermore, IL-36 was reported to effectively reduce the production of melanin in human melanocytes (18) . The gene expression of IL-36α was significantly higher in both lesional in addition to non-lesional scalp biopsies of individuals with alopecia areata than in heathy controls, with a significant relation between the expression in alopecia areata lesions and the disease severity (19) .…”

Section: Discussionmentioning

confidence: 89%

Assessment of Serum Interleukin-36γ Level in Patients with Warts

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: The human papillomavirus (HPV) is the causative agent of harmless verrucous overgrowths called warts. Their eradication depends on effective T helper 1/cytotoxic T cells cellular immunity. Interleukin (IL)-36 agonist cytokines are secreted mainly by epithelial cells, such as keratinocytes, in response to infections or inflammatory condition. These cytokines enhance innate immune response and promote the activation of Th1 and Th17 cells. Aim: The study aimed to evaluate IL-36γ serum level in persons with warts in comparison with healthy controls in order to investigate the potential function of Interleukin-36 in the immune response against this common skin viral infection. Subjects and Methods: In this case-control study, participants were forty people with warts who were recruited from the Dermatology Outpatient Clinics at Suez Canal University Hospitals in Ismailia city, Egypt, as well as forty people who served as healthy control group. Results: Serum Interleukin-36γ level was significantly greater in patients with warts than in healthy controls (p < 0.001). However, there was no significant relation amongst IL-36γ level & clinical data gathered from individuals affected by warts (age, gender, site, number, clinical type, and recurrence). Conclusion: Serum level of IL-36γ was significantly increased in patients with warts compared to controls. This high serum level of Interleukin-36γ might highlight the possible role of IL-36γ in promoting the cell-mediated immune response against human papillomavirus.

show abstract

Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review

Chen

et al. 2023

Genes

View full text Add to dashboard Cite

Alopecia areata (AA) is a chronic, non-scarring, immune-mediated skin disease that affects approximately 0.5–2% of the global population. The etiology of AA is complex and involves genetic and environmental factors, with significant advancements in genetic research occurring in recent years. In addition to well-known genes such as PTPN22, CTLA4, and IL2, which have been widely supported as being associated with AA, an increasing number of specific gene-related loci have been discovered through advances in genetic research. For instance, gene analysis of microRNAs can reveal the critical role of miRNAs in regulating gene expression, aiding in the understanding of cellular and organismal functional regulatory mechanisms. Furthermore, numerous studies have confirmed the existence of correlations between AA and other immune-related diseases. Examples include hyperthyroidism and rheumatoid arthritis. By understanding the interrelationships between AA and other immune diseases, we can further comprehend potential shared genetic foundations or pathogenic mechanisms among different diseases. Genetic research plays a crucial role in unraveling the pathogenesis of AA, as the identification of genetic variations associated with AA can assist in formulating more effective and targeted treatment strategies.

show abstract

The alterations of gene expression of interleukin‐36α and interleukin‐37 between alopecia areata patients and healthy controls

Cited by 3 publications

References 11 publications

Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real‐life experience in a tertiary referral centre

Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real‐life experience in a tertiary referral centre

Assessment of Serum Interleukin-36γ Level in Patients with Warts

Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review

Contact Info

Product

Resources

About